[Asia Economy Reporter Hyunseok Yoo] Ewone Compotech announced on the 25th that it is in negotiations to secure exclusive Asian market rights for a next-generation colorectal cancer treatment developed by Professor Scott Waldman's team in the United States.
The pipeline currently under negotiation is a broad program that can prevent or treat metabolic syndrome, including colorectal cancer, obesity, and diabetes, using GCC ligands regardless of the formulation type (oral pills, injections, or health supplements).
Professor Scott Waldman's team is conducting a Phase 2 clinical trial approved by the U.S. FDA with support from the U.S. Department of Defense to prove the safety and efficacy of this program.
A representative from Ewone Compotech explained, “Currently, clinical trials are underway at three renowned cancer centers in the U.S. involving 230 patients, using linaclotide among the GCC ligands to confirm the preventive treatment effect for colorectal cancer.”
Linaclotide is a type of GCC ligand identified as a cause of irritable bowel syndrome, chronic constipation, and colorectal cancer. It is the main ingredient of Linzess, an FDA-approved drug already marketed for treating irritable bowel syndrome and chronic constipation. Professor Scott Waldman selected it as a new treatment for colorectal cancer and is conducting Phase 2 clinical trials.
Professor Scott Waldman was the clinical chief responsible for the blockbuster drug Linzess, used to treat irritable bowel syndrome and chronic constipation. He stated, “I was scheduled to attend Ewone Compotech’s regular shareholders’ meeting on the 30th to directly proceed with this contract, but due to the indefinite postponement of my visit to Korea caused by the COVID-19 situation, we agreed to proceed with the contract signing via email.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
